Iron-catalysed C-3 functionalisation of indolizines via C–H bond cleavage Xu Shao-hong

Department of Chemistry and Chemical Engineering; Xinxiang University; Xinxiang 453003, P. R. China

The synthesis of 3,3'-(aryImethylene)diindolizine with a FeCl₃·6H₂O catalyst has been achieved with excellent efficiency at room temperature. Various indolizines were prepared by the reaction with either aromatic or aliphatic aldehydes to produce di- or triheteroaryImethanes.

Keywords: indolizine, C-3 functionalisation, benzylation, iron-catalysed synthesis

Transition metal-catalysed C–C bond formation reactions involving C–H bond activation^{1–5} are distinguished from the traditional transition metal-catalysed reactions by fewer steps and less wastage. The older methods need prefunctionalisation of both reaction partners. These transformations exhibit even more advantages for arylation, alkenylation, alkynylation and alkylation of heteroaromatics, because some important types of heteroaryl organometallic compounds have proven challenging to synthesise and may even be insufficiently stable to participate in cross-coupling processes. The regioselective conversion of C–H to C–C bonds would result in shortening of synthetic schemes by allowing the use of readily available starting materials.^{6–11}

Indolizines are interesting structures in a wide variety of natural products with useful biological activities¹¹⁻¹⁶ and pharmaceutical properties.^{17–22} The functionalisation of indolizines have attracted considerable interest in the past and metal-catalysed direct functionalisation of indolizines has been explored recently.^{17–29}

Triaryl- and triheteroarylmethanes have attracted much attention from organic chemists and many such compounds have found widespread applications in synthetic, medicinal, and industrial chemistry.³⁰⁻³² Triarylmethanes can be synthesised by a number of methods, but most of them are multi-step processes and require harsh conditions, while Friedel-Crafts arene alkylation is a major technique in the formation of new arene-alkane C-C bonds.33-38 Bis-indolylalkanes obtained by the condensation of indoles with aromatic or aliphatic aldehydes requires the use of several Brønsted and Lewis acids.³⁹⁻⁴¹ In the quest to develop a mild and practical protocol for the synthesis of triaryl-/triheteroarylmethanes, we speculated that iron(III) catalyst, which has recently been shown to catalyse a variety of C-C/C-N bond forming reactions,⁴²⁻⁴⁷ might be ideal for effecting the condensation of aldehydes and activated arenes.

We investigated the electrophilic substitution reaction of indolizines with aldehydes in the presence of a catalytic amount of iron(III) chloride at room temperature to form triheteroarylmethane derivatives, the preparation of which usually requires multi-step processes and harsh conditions.

Results and discussion

The preliminary results that illustrate the efficiency and versatility of FeCl₃-promoted indolizines' condensation with aldehydes to afford triheteroarylmethanes-3,3'-(phenylmethylene) diiindolizine-1-carbonitrile are described in this work.

The formation of a 1,1-bis-indolizine-methane product was not observed in the presence of FeCl₂, FeBr₂, FeSO₄, Fe(acac)₂ and Fe₂O₃ (Table 1, entries 1–5). Comparable yields were obtained when CuCl₂2H₂O and Cu(OAc)₂H₂O were used as catalysts under 60 °C for 2 h in CH₃CN (Table 1, entries 6

* Correspondent. E-mail: shaohong_xu@126.com

and 7). However, AlCl₃ was a much more effective catalyst and FeCl₃ gave the best results at room temperature (Table 1, entries 8 and 9). The transformation completed under 60 °C in 2h in 96 % isolated yield (Table 1, entry 10). Otherwise, CH₃CN performed better than other apolar aprotic solvents (CCl₄, THF, Et₂O) and aprotic polar solvents (DMF, DMSO) (Table 1, entries 11–18). Furthermore, this transformation was very practical as it does not need the use of bases or ligands and the rigorous exclusion of air/moisture was not required.

These optimised conditions have been applied successfully for the condensation of a variety of indolizines with aldehydes. The results are summarised in Table 2. They showed that both electron-withdrawing and electron-donating substituents had no significant effect on the yields (Table 2, entries 1–3). The presence of a substituent on the *ortho*-position of aromatic aldehydes did not cause any decrease in the reaction yields (Table 2, entry 4). In the case of aliphatic aldehydes such as *n*-butyraldehyde, the reaction proceeded satisfactory in comparison with aromatic aldehydes (Table 2, entry 5). Attempts to use other indolizine derivatives in the reaction with benzaldehyde were mostly successful. Methyl, ethyl and *n*-butyl indolizine-1-carboxylate were all compatible with the catalyst system (Table 2, entries 6–8).

 Table 1
 Optimisation of reaction conditions^a



Entry	Catalyst	Solvent	Yield/% ^b
1	FeCl ₂ ·4H ₂ O	CH₃CN	0
2	FeBr ₂	CH₃CN	0
3	FeSO₄	CH₃CN	0
4	Fe(acac) ₂	CH₃CN	0
5	Fe ₂ O ₃	CH₃CN	0
6	CuCl ₂ 2H ₂ O	CH₃CN	30°
7	Cu(OAc) ₂ ·H ₂ O	CH₃CN	22°
8	FeCl ₃ ·6H ₂ O	CH₃CN	92
9	AICI3	CH₃CN	81
10	FeCl ₃ 6H ₂ O	CH₃CN	96°
11	FeCl ₃	CH ₂ CI ₂	46
12	FeCl ₃	CHCI₃	51
13	FeCl ₃	CCI ₄	60
14	FeCl ₃	THF	39
15	FeCl ₃	Et ₂ O	38
16	FeCl ₃	EtOAc	23
17	FeCl ₃	DMF	16
18	FeCl ₃	DMSO	17

^aReaction conditions: indolizine-1-carbonitrile (0.4 mmol), benzaldehyde (0.2 mmol), catalyst (0.01 mmol), solvent (2 mL), RT, 2 h. ^bIsolated yield. ^cPerformed at 60 °C for 2 h.







^aReaction conditions: Indolizines (0.4 mmol), aldehydes (0.2 mmol), FeCl₃6H₂O (0.01 mmol),CH₃CN (2 mL), RT, 2h.
^bIsolated yield.

Conclusion

In conclusion, we report our results concerning the study of indolizines' C-3 functionalisation involving C–H activation afford a diversity of C-3 substitution by benzylation. We have introduced a well-precedented electrophilic substitution reaction of indolizines with aldehydes in the presence of a catalytic amount of $FeCl_3 6H_2O$ under mild conditions to afford triheteroarylmethane derivatives. As part of the continuing exploration of new chemistry of the indolizine ring, this reaction has potential applications in organic syntheses and industrial processes.

Experimental

Starting materials were purchased from common commercial sources and solvents were all purified and dried according to standard methods prior to use. Column chromatography was carried out on SiO₂ (300–400 mesh). ¹H NMR spectra were recorded with a Bruker 400 MHz spectrometer using TMS as internal standard. ¹³C NMR spectra were recorded at 100 MHz using TMS as internal standard. The multiplicities are reported as follows: singlet (s), doublet (d), doublet of doublets (dd), multiplet (m). Mass spectroscopy data were collected with HRMS-EI and HRMS-ESI instrument.

Synthesis of triheteroarylmethane

A mixture of indolizines (0.4 mmol), aldehydes (0.2 mmol), $FeCl_3$ (5 mol%), in CH₃CN (2 mL) was stirred at room temperature for 2 h. Afterward, the mixture was filtered through a pad of Celite. The solvent was evaporated under reduced pressure, and the residue was subjected to flash column chromatography to obtain the desired product.

3,3'-((4-Methoxyphenyl)methylene)diindolizine-1-carbonitrile (**T** 2-1): Purification by column chromatography (silica gel, ethyl acetate/ petroleum ether = 1/3, v/v) gave a white solid; m.p. 257–259 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.63–7.69 (m, 4 H), 7.11 (t, J = 8.0 Hz, 2 H), 7.06 (d, J = 7.6 Hz, 2 H), 7.00 (d, J = 8.0 Hz, 2 H), 6.73 (t, J = 8.0 Hz, 2 H), 6.35 (s, 2 H), 5.69 (s, 1 H), 3.81 (s, 3 H). ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 138.8, 129.4, 127.8, 123.7, 122.4, 118.2, 117.2, 116.6, 114.8, 113.3, 81.4, 55.3, 40.3. HRMS (EI) Calcd for C₂₆H₁₈N₄O (M⁺) 402.1481; found 402.1490.

3,3'-(Phenylmethylene)diindolizine-1-carbonitrile (**T 2-2**) Purification by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/3, v/v) gave a white solid; m.p. 249–250 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.68 (t, J = 7.2 Hz, 4 H), 7.37 (t, J = 7.2 Hz, 3 H), 7.17 (t, J = 7.2 Hz, 2 H), 7.11–7.12 (m, 2 H), 6.74 (t, J = 7.2 Hz, 2 H), 6.34 (s, 2 H), 5.80 (s, 1 H). ¹³C NMR (100 MHz, CDCl₃) δ 138.8, 136.1, 129.4, 128.5, 128.4, 123.7, 123.4, 122.4, 118.1, 117.3, 116.5, 113.4, 81.4, 41.0. HRMS (EI) Calcd for C₂₅H₁₆N₄ (M⁺) 372.1375; found 372.1380.

3,3'-((4-Chlorophenyl)methylene)diindolizine-1-carbonitrile (**T** 2-3): Purification by column chromatography (silica gel, ethyl acetate/ petroleum ether = 1/3, v/v) afforded as a white solid; m.p. 260– 262 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.69 (d, *J* = 9.2 Hz, 2 H), 7.65 (d, *J* = 8.4 Hz, 2 H), 7.38 (t, *J* = 8.4 Hz, 2 H), 7.10–7.16 (m, 4 H), 6.76 (t, *J* = 8.4 Hz, 2 H), 6.35 (s, 2 H), 5.77 (s, 1 H). ¹³C NMR (100 MHz, CDCl₃) δ 138.9, 134.7, 134.4, 129.8, 129.7, 123.6, 122.8, 122.6, 118.2, 117.3, 116.4, 113.5, 81.6, 40.4. HRMS (EI) Calcd for C₂₃H₁₅ClN₄ (M⁺) 406.0985; found 406.0989.

3,3'-(*Thiophen-2-ylmethylene*)diindolizine-1-carbonitrile (**T 2-4**): Purification by column chromatography (silica gel, ethyl acetate/ petroleum ether = 1/3, v/v) gave a white solid; m.p. 213–215 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.66–7.72 (m, 4 H), 7.32 (d, J = 7.6 Hz, 2 H), 7.13 (t, J = 8.0 Hz, 2 H), 7.00 (t, J = 8.0 Hz, 1 H), 6.74–6.80 (m, 3 H), 6.51 (s, 2 H), 6.07 (s, 1 H). ¹³C NMR (100 MHz, CDCl₃) δ 139.1, 138.8, 127.4, 127.1, 126.3, 123.6, 123.1, 122.6, 118.3, 117.0, 116.5, 113.5, 81.5, 36.1. HRMS (EI) Calcd for C₂₃H₁₄N₄S (M⁺) 378.0939; found 378.0930.

3,3'-(Butane-1,1-diyl)diindolizine-1-carbonitrile (**T 2-5**): Purification by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/3, v/v) gave a white solid; m.p. 187–189 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 7.80 (d, J = 7.2 Hz, 2 H), 7.63 (d, J = 7.2 Hz, 2 H), 7.07 (t, J = 7.6 Hz, 2 H), 6.89 (s, 2 H), 6.75 (t, J = 6.8 Hz, 2 H), 4.54 (t, J = 7.2 Hz, 1 H), 2.20–2.26 (m, 2 H), 1.44–1.49 (m, 2 H), 1.01 (t, J = 7.6 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃) δ 138.6, 124.0, 123.3, 122.1, 118.2, 116.7, 115.4, 113.4, 81.2, 34.6, 33.6, 20.8, 13.9. HRMS (EI) Calcd for C₂₂H₁₈N₄ (M⁺) 338.1531; found 338.1528.

Dimethyl 3,3'-(phenylmethylene)diindolizine-1-carboxylate (**T 2-6**): Purification by column chromatography (silica gel, ethyl acetate/ petroleum ether = 1/3, v/v) gave a white solid; m.p. 211–212 °C. (lit:⁴⁸ 210–211 °C) ¹H NMR (400 MHz, CDCl₃, TMS) δ 8.27 (d, J = 8.0 Hz, 2 H), 7.64 (d, J = 7.6 Hz, 2 H), 7.34–7.36 (m, 3 H), 7.19 (d, J = 7.6 Hz, 2 H), 7.09 (t, J = 8.0 Hz, 2 H), 6.67 (t, J = 6.8 Hz, 2 H), 6.63 (s, 2 H), 5.72 (s, 1 H), 3.82 (s, 6 H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 137.1, 136.7, 129.2, 128.6, 128.0, 123.3, 123.2, 122.2, 120.0, 116.8, 112.8, 103.0, 50.9, 41.3. HRMS (EI) Calcd for C₂₇H₂₂N₂O₄ (M⁺) 438.1580; found 438.1587. Diethyl 3,3'-(phenylmethylene)diindolizine-1-carboxylate (**T** 2-7): Purification by column chromatography (silica gel, ethyl acetate/ petroleum ether = 1/3, v/v) gave a white solid; m.p. 194–195 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 8.27 (d, J = 7.6 Hz, 2 H), 7.64 (d, J = 7.2 Hz, 2 H), 7.34–7.35 (m, 3 H), 7.18–7.20 (m, 2 H), 7.06–7.10 (m, 2 H), 6.64–6.67 (m, 4 H), 5.72 (s, 2 H), 4.29–4.33 (m, 2 H), 1.35 (t, J = 7.2 Hz, 6 H). ¹³C NMR (100 MHz, CDCl₃) δ 164.9, 137.2, 136.5, 129.2, 128.6, 127.9, 123.3, 123.2, 122.1, 120.1, 116.9, 112.7, 103.5, 59.5, 41.3, 14.6. HRMS (EI) Calcd for C₂₉H₂₆N₂O₄(M⁺) 466.1893; found 466.1899.

Dibutyl 3,3'-(*phenylmethylene*)*diindolizine-1-carboxylate* (**T** 2-8): Purification by column chromatography (silica gel, ethyl acetate/ petroleum ether = 1/3, v/v) gave a yellow solid; m.p. 176–177 °C. ¹H NMR (400 MHz, CDCl₃, TMS) δ 8.27 (d, *J* = 7.6 Hz, 2 H), 7.64 (d, *J* = 7.2 Hz, 2 H), 7.34–7.35 (m, 3 H), 7.18–7.20 (m, 2 H), 7.06–7.10 (m, 2 H), 6.64–6.67 (m, 4 H), 5.72 (s, 2 H), 4.29–4.33 (m, 2 H), 1.35 (t, *J* = 7.2 Hz, 6 H). ¹³C NMR (100 MHz, CDCl₃) δ 165.0, 137.2, 136.5, 129.2, 128.6, 127.9, 123.3, 123.2, 122.1, 120.1, 117.0, 112.6, 103.5, 63.5, 41.3, 31.0, 19.3, 13.8. HRMS (EI) Calcd for C₃₃H₃₄N₂O₄ (M⁺) 522.2519; found 522.2510.

Received 1 April 2012; accepted 27 April 2012 Paper 1201241 doi: 10.3184/174751912X13383077583357 Published online: 8 August 2012

References

- 1 V. Ritleng, C. Sirlin and M. Pfeffer, Chem. Rev., 2002, 102, 1731.
- 2 C.I. Herrerías, X. Yao, Z. Li and C.J. Li, Chem. Rev., 2007, 107, 2546.
- 3 D. Alberico, M.E. Scott and M. Lautens, Chem. Rev., 2007, 107, 174.
- 4 G.P. McGlacken and L.M. Bateman, Chem. Soc. Rev., 2009, 38, 2447-.
- 5 I.V. Seregin and V. Gevorgyan, Chem. Soc. Rev. 2007, 36, 1173.
- 6 Y.J. Park, J.-W. Park and C.-H. Jun, Acc. Chem. Res., 2008, 41, 222.
- 7 L.C. Lewis, R.G. Bergman and J.A. Ellman, Acc. Chem. Res., 2008, 41, 1013.
- 8 O. Daugulis, H.-Q. Do and D. Shabashov, Acc. Chem. Res., 2009, 42, 1074.
- 9 L. Ackermann, R. Vicente and A.R. Kapdi, Angew. Chem., Int. Ed., 2009, 48, 9792.
- 10 C.-L. Sun, B.-J. Li and Z.-J. Shi, Chem. Commun., 2010, 46, 677.
- 11 T.W. Lyons and M.S. Sanford, Chem. Rev., 2010, 110, 1147.
- F.T. Swinbourne, J. Hunt and K. Klinkert, <u>Adv. Heterocycl. Chem.</u>, 1978, 23, 103.
- 13 W. Flitsch, Comprehensive heterocyclic chemistry, eds A.R. Katrizky and C.W. Rees, Pergamon, Oxford, 1984, Vol. 4, p.476.
- 14 J.P. Michael, Nat. Prod. Rep., 1995, 12, 535.
- 15 J. Mahon, L.K. Mehta, R.W. Middleton, J. Parrick and H.K. Rami, J. Chem. Res., (S), 1992, 362.

- 16 J.P. Michael, Nat. Prod. Rep. 2002, 19, 742.
- 17 J. Bermudez, C.S. Fake, G.F. Joiner, K.A. Joiner, F.D. King, W.D. Miner and G.J. Sanger, J. Med. Chem., 1990, 33, 1924.
- 18 S. Okada, K. Sawada, A. Kozo, S. Watarabe and H. Tanaka, Brit. UK Pat. Appl. GB 2287706, 1995; *Chem. Abstr.*, 1995, **124**, 175847.
- 19 S. Hagishita, M. Yamada, K. Shirahase, T. Okada, Y. Murakami, Y. Ito, T. Matsuura, M. Wada, T. Kato, M. Ueno, Y. Chikazawa, K. Yamada, T. Ono, I. Teshirogi and M. Ohtani, *J. Med. Chem.*, 1996, **39**, 3636.
- 20 O.B. Ostby, B. Dalhus, L.-L. Gundersen, F. Rise, A. Bast and G.R.M.M. Haenen, *Eur. J. Org. Chem.*, 2000, 3763.
- 21 L. Halab, J.A.J. Becker, Z. Darula, D. Tourwe, B.L. Kieffer, F. Simonin and W.D. Lubell, J. Med. Chem., 2002, 45, 5353.
- 22 W.H. Pearson and E.J. Hembre, J. Org. Chem., 1996, 61, 5546.
- 23 B. Liu, X. Qin, K. Li, X. Li, Q. Guo, J. Lan and J. You, *Chem. Eur. J.*, 2010, 16, 11836.
- 24 D. Lapointe, T. Markiewicz, C.J. Whipp, A. Toderian and K. Fagnou, J. Org. Chem., 2011, 76, 749.
- 25 T.P. Pathak and M.S. Sigman, Org. Lett., 2011, 13, 2774.
- 26 L. Huang, T. Niu, J. Wu and Y. Zhang, J. Org. Chem., 2011, 76, 1759.
- 27 Y. Yang, L. Chen, Z. Zhang and Y. Zhang, Org. Lett., 2011, 13, 1342.
- 28 Y. Yang, K. Cheng and Y. Zhang, Org. Lett., 2009, 11, 5606.
- 29 C.-H. Park, V. Ryabova, I.V. Seregin, A.W. Sromek and V. Gevorgyan, Org. Lett., 2004, 6, 1159.
- 30 M.S. Shchepinov and V.A. Korshun, Chem. Soc. Rev., 2003, 32, 170.
- 31 D.F. Duxbury, Chem. Rev., 1993, 93, 381.
- 32 R.J. Schnitzer and F. Hawking, *Experimental chemotherapy*, Academic Press, New York, 1963; Vol. I.
- 33 M. Bandini and A. Melloni, Umani-Ronchi, A. Angew. Chem., Int. Ed., 2004, 43, 550.
- 34 R.W. Dugger, J.A. Ragan and B. Ripin, Org. *Process Res. Dev.*, 2005, 9, 253.
- 35 L. Simon and J.M. Goodman, J. Org. Chem., 2010, 75, 589.
- 36 Y. Liu, D. Shang, X. Zhou, Y. Zhu, L. Lin, X. Liu, X. Feng, Org. Lett., 2010, 12, 180.
- 37 Y. Hui, Q. Zhang, J. Jiang, L. Lin, X. Liu and X.J. Feng, Org. Chem., 2009, 74, 6878.
- 38 L. Hong, C. Liu, W. Sun, L. Wang, K. Wong and R. Wang, Org. Lett., 2009, 11, 2177.
- 39 H.E. Ungnade and E.W. Crandall, J. Am. Chem. Soc., 1949, 71, 2209.
- 40 E.F. Pratt and L.Q. Green, J. Am. Chem. Soc., 1953, **75**, 275. 41 S.-J. Ji, M.-F. Zhou, D.-G. Gu, Z.-Q. Jiang and T.-P. Loh, Eur. J. Org.
- *Chem.*, 2004, 1584.
- 42 A. Correa, O.G. MancheMo and C. Bolm, <u>Chem. Soc. Rev.</u>, 2008, 37, 1108.
- 43 C. Bolm, J. Legros, J. Le Paih and L. Zani, Chem. Rev., 2004, 104, 6217.
- 44 H. Egami and T. Katsuki, J. Am. Chem. Soc., 2007, 129, 8940.
- 45 A. Correa, M. Carril and C. Bolm, Chem.-Eur. J., 2008, 14, 10919.
- 46 A. Correa, S. Elmore and C. Bolm, Chem.-Eur. J., 2008, 14, 3527.
- 47 D. Guo, H. Huang, J. Xu, H. Jiang and H. Liu, Org. Lett., 2008, 10, 4513.
- 48 M. Yasuyoshi, H. Yuji, H. Hiroko, T. Shoji, J. Heter. Chem., 1991, 28, 45.